- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02633189
Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer (BEVERLY)
March 23, 2023 updated by: National Cancer Institute, Naples
A Randomized Open-label Phase 3 Trial Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer
The purpose of this study is to test whether the combination of bevacizumab and erlotinib can prolong progression free survival as compared with erlotinib alone as first-line treatment in patients with non small cell lung cancer (NSCLC) with activating mutation of EGFR.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
The co-primary objectives are to assess investigator-assess, and blinded independent centrally-reviewed progression-free survival .
Study Type
Interventional
Enrollment (Anticipated)
200
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Alessandria, Italy
- A.S.O. SS Antonio e Biagio e Cesare Arrigo
-
Avellino, Italy
- A.O. S. Giuseppe Moscati
-
Aviano, Italy
- Centro Riferimento Oncologico
-
Benevento, Italy
- AO G. Rummo
-
Brindisi, Italy
- Ospedale Senatore Antonio Perrino
-
Campobasso, Italy
- Ospedale A. cardarelli
-
Camposampiero, Italy
- U.L.S.S. 15 Veneto
-
Catania, Italy
- Policlinico Vittorio Emanuele
-
Catania, Italy
- A.O. Garibaldi Nesima
-
Catania, Italy
- Centro Clinico Diagnostico G.B. Morgagni
-
Faenza, Italy
- Ospedale Civile per gli Infermi
-
Fano, Italy
- Ospedale S. Croce
-
Ferrara, Italy
- A.O.U. Arcispedale Sant'Anna
-
Genova, Italy
- Ospedale Villa Scassi
-
Guastalla, Italy
- Ospedale di Guastalla
-
Lecce, Italy
- A.O. Vito Fazzi
-
Meldola, Italy
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
-
Milano, Italy
- Istituto Europeo di Oncologia
-
Milano, Italy
- Istituto Nazionale Tumori
-
Milano, Italy
- Ospedale San Paolo
-
Mirano, Italy
- A.O. U.L.S.S. 13
-
Modena, Italy
- A.O.U. Policlinico Modena
-
Napoli, Italy
- A.O.U. Seconda Universita di Napoli
-
Napoli, Italy
- Istituto Nazionale Tumori Fondazione G. Pascale
-
Napoli, Italy, 80131
- Azienda Ospedaliera Cardarelli
-
Napoli, Italy
- AORN Ospedale dei Colli - Osp Monaldi
-
Negrar, Italy
- Istituto Sacro Cuore Don Calabria
-
Novara, Italy
- A.O.U. Maggiore della Carità
-
Padova, Italy
- Istituto Oncologico Veneto
-
Palermo, Italy
- Policlinico Giaccone
-
Pavia, Italy
- Fondazione Salvatore Maugeri
-
Perugia, Italy
- Osp. S. Maria Della Misericordia
-
Pesaro, Italy
- A.O. Ospedali Riuniti Marche Nord
-
Piacenza, Italy
- Ospedale Guglielmo da Saliceto
-
Potenza, Italy
- A.O. San Carlo
-
Ravenna, Italy
- Ospedale Umberto I
-
Ravenna, Italy
- Ospedale Santa Maria delle Croci - AUSL
-
Rimini, Italy
- Ospedale degli Infermi Rimini - Ospedale Cervesi Cattolica
-
Rionero in Vulture, Italy
- IRCCS Centro di Riferimento Oncologico Basilicata
-
Roma, Italy
- Istituto Regina Elena
-
Roma, Italy
- Ospedale S. Giovanni Calibita Fatebenefratelli
-
Roma, Italy
- Ospedale Camillo Forlanini
-
Roma, Italy
- Policlinico Universitario Campus Bio Medico
-
Sondrio, Italy
- Ospedale di Sondrio
-
Sora, Italy
- Ospedale Fabrizio Spaziani di Frosinone
-
Trieste, Italy
- Ospedale Maggiore
-
Udine, Italy
- Azienda Ospedaliero-Universitaria S.M. della Misericordia di Udine
-
Vercelli, Italy
- Ospedale S. Andrea
-
Verona, Italy
- A.O.U. Integrata
-
Viterbo, Italy
- ASL Viterbo - Ospedale Belcolle
-
-
MO
-
Carpi, MO, Italy, 41012
- Ospedale Ramazzini, Day Hospital Oncologico
-
-
PA
-
Palermo, PA, Italy, 90146
- Casa di Cura La Maddalena S.p.A., Dipartimento Oncologico
-
-
PO
-
Prato, PO, Italy, 59100
- Ospedale di Prato
-
-
TN
-
Trento, TN, Italy, 38100
- Ospedale S. Chiara
-
-
VI
-
Vicenza, VI, Italy, 36100
- Ospedale S. Bortolo ULSS 6, U.O. di Oncologia Medica
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age ≥18 years
- Histological documentation of primary non squamous lung carcinoma
- Stage IV or IIIB disease with supraclavicular metastatic nodes (according to TNM 7th edition)
- Activating epidermal growth factor receptor mutation (exon19 deletion or exon 21 L858R mutation or other activating/sensitizing mutations, such as exon 21 L861Q, exon 18 G719S, G719A and G719C, exon 20 S768I and V769L). EGFR mutation testing must be performed at participating centres in a certified lab (AIOM-SIAPEC program or other European Quality Assurance [EQA] schemes)
- Clinical or radiologic evidence of disease (at least one target or non target lesion according to RECIST 1.1)
- ECOG performance status 0 to 2
- Life expectancy > 3 months
- Use of an acceptable mean of contraception for men and women of childbearing potential
- Written informed consent.
Exclusion Criteria:
- EGFR T790M mutation alone or exon 20 insertions as unique mutation
- Tumors with a squamous component
- Prior chemotherapy or any other medical treatment for advanced NSCLC (previous neoadjuvant or adjuvant chemotherapy is allowed if > 6 months before randomisation)
- Radiotherapy to any site for any reason within 28 days prior to randomization (palliative radiotherapy to bone lesions is allowed if ≥ 14 days before randomization)
- Full-dose anticoagulation with warfarin
- Current or recent (within 10 days of enrolment) use of aspirin (>325 mg/day) or chronic use of other full-dose nonsteroidal anti-inflammatory drugs (NSAIDs) with anti-platelet activity
- Receiving any medications or substances that are strong or moderate inhibitors of cytochrome P450 3A4 (CYP3A4) are prohibited =< 7 days prior to registration
- Receiving any medications or substances that are inducers of CYP3A4 use of inducers are prohibited =< 7 days prior to registration
Inadequate coagulation parameters:
- activated partial thromboplastin time (APTT) >1.5 x the upper limit of normal (ULN) or
- INR >1.5
Inadequate liver function, defined as:
- serum (total) bilirubin >1.5 x ULN
- AST/SGOT or ALT/SGPT >2.5 x ULN
Inadequate renal function, defined as:
- serum creatinine >2.0 mg/dl or >177 micromol/l
- urine dipstick for proteinuria >2+. Patients with > o = 1+ proteinuria at baseline dipstick analysis must undergo a 24-hour urine collection and must demonstrate ≤1g of protein in their 24-hour urine collection.
- Pregnancy or breast-feeding
- Inadequately controlled hypertension (defined as systolic blood pressure >150 and/or diastolic blood pressure >100 mmHg on antihypertensive medications)
- History of gross hemoptysis within 3 months prior to randomization unless definitively treated with surgery or radiation
- History of any of the following within 6 months prior to randomisation: serious systemic disease, unstable angina, New York Heart Association (NYHA) Grade 2 or greater Congestive Heart Failure (CHF), unstable symptomatic arrhythmia requiring medication, clinically significant peripheral vascular disease, abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess
- Serious, non-healing wound, ulcer, or bone fracture
- Evidence of bleeding diathesis or coagulopathy or other serious or acute internal bleeding within 6 months prior to randomization
- Central Nervous System (CNS) bleeding; history or clinical evidence of CNS stroke (hemorrhagic or thrombotic) within the last 6 months
- In-patient surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to randomization
- Minor surgical procedure, fine needle aspirations or core biopsy within 7 days prior to randomization
- Anticipation of need for a major surgical procedure during the course of the study
- Inability to take oral medication or requirement for intravenous (IV) alimentation or total parenteral nutrition with lipids, or prior surgical procedures affecting absorption
- Evidence of confusion or disorientation, or history of major psychiatric illness that may impair the patient's understanding of the Informed Consent Form or his/her ability to comply with study requirements
- Any other invasive malignancies within 5 years (except for adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer or surgically resected prostate cancer with normal PSA)
- Brain metastasis
- Patients who have had radiotherapy ≥ 4 weeks prior to the first dose of study treatment, but who are still experiencing acute toxic effects of radiotherapy
- Known HIV positive patients (patients with both acute or chronic infection are excluded)
- Active HBV or HCV infection (patients with chronic non-active infection are eligible)
- Any already known inflammatory changes of the surface of the eye at baseline
- Any other concomitant pathologies or laboratory alterations that prevent or contraindicate the use of erlotinib or bevacizumab.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: erlotinib
|
given orally 150 mg daily
|
Experimental: erlotinib and bevacizumab
|
given orally 150 mg daily
15 mg/kg intravenously every 21 days.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
progression free survival
Time Frame: up to 2 years
|
as determined by investigator
|
up to 2 years
|
progression free survival
Time Frame: up to 2 years
|
as determined by an independent central review board blinded to study treatment
|
up to 2 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
overall survival
Time Frame: 1 year
|
1 year
|
changes in quality of life scores from baseline
Time Frame: up to 2 years
|
up to 2 years
|
number of patients with complete and partial responses , investigator assessed
Time Frame: 6 months
|
6 months
|
number of patients with complete and partial responses , centrally reviewed
Time Frame: 6 months
|
6 months
|
worst grade toxicity per patient
Time Frame: up to one year
|
up to one year
|
progression free survival according to type of EGFR mutation (exon 19del, exon 21L858R, other)
Time Frame: 2 years
|
2 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
number and type of EGFR mutations in plasma samples
Time Frame: up to 2 years
|
samples taken at baseline, 6 weeks, 6 months, and at progression
|
up to 2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Cesare Gridelli, M.D., S.G.Moscati Hospital
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Deng Z, Qin Y, Liu Y, Zhang Y, Lu Y. Role of Antiangiogenic Agents Combined With EGFR Tyrosine Kinase Inhibitors in Treatment-naive Lung Cancer: A Meta-Analysis. Clin Lung Cancer. 2021 Jan;22(1):e70-e83. doi: 10.1016/j.cllc.2020.08.005. Epub 2020 Sep 18.
- Piccirillo MC, Bonanno L, Garassino MC, Esposito G, Dazzi C, Cavanna L, Burgio MA, Rosetti F, Rizzato S, Morgillo F, Cinieri S, Veccia A, Papi M, Tonini G, Gebbia V, Ricciardi S, Pozzessere D, Ferro A, Proto C, Costanzo R, D'Arcangelo M, Proietto M, Gargiulo P, Di Liello R, Arenare L, De Marinis F, Crino L, Ciardiello F, Normanno N, Gallo C, Perrone F, Gridelli C, Morabito A. Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial. J Thorac Oncol. 2022 Sep;17(9):1086-1097. doi: 10.1016/j.jtho.2022.05.008. Epub 2022 Jun 1.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 1, 2016
Primary Completion (Anticipated)
December 1, 2023
Study Completion (Anticipated)
July 1, 2024
Study Registration Dates
First Submitted
December 15, 2015
First Submitted That Met QC Criteria
December 15, 2015
First Posted (Estimate)
December 17, 2015
Study Record Updates
Last Update Posted (Actual)
March 24, 2023
Last Update Submitted That Met QC Criteria
March 23, 2023
Last Verified
March 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Protein Kinase Inhibitors
- Erlotinib Hydrochloride
- Bevacizumab
Other Study ID Numbers
- BEVERLY
- 2015-002235-17 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-squamous Non-small Cell Lung Cancer
-
AIO-Studien-gGmbHAstraZenecaTerminatedNSCLC | Non-squamous Non-small Cell Lung Cancer Stage II | Non-squamous Non-small Cell Lung Cancer Stage IIIA | Non-squamous Non-small Cell Lung Cancer Stage IIIB | Activating EGFR MutationGermany
-
Peking University First HospitalMerck Sharp & Dohme LLCNot yet recruitingAdvanced Non-squamous Non-small-cell Lung Cancer | Metastatic Non-squamous Non Small Cell Lung Cancer | Recurrent Non-Squamous Non-Small Cell Lung CancerChina
-
Western Regional Medical CenterTerminatedNon-squamous Cell Non-Metastatic Non-Small Cell Lung Cancer | Squamous Cell Non-Metastatic Non-Small Cell Lung CancerUnited States
-
European Organisation for Research and Treatment...WithdrawnSquamous Non-small Cell Lung Cancer | Non-Squamous Non-small Cell Lung Cancer
-
Bristol-Myers SquibbNo longer availableNon-squamous Non-Small Cell Lung Cancer | Squamous Non-Small Cell Lung CancerBrazil, Canada
-
National Cancer Institute (NCI)Active, not recruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Unresectable Lung Non-Small Cell Carcinoma | Unresectable Lung Non-Squamous Non-Small Cell Carcinoma | Metastatic...United States
-
National Cancer Institute (NCI)Active, not recruitingStage IIIA Lung Non-Small Cell Cancer AJCC v7 | Advanced Lung Non-Squamous Non-Small Cell Carcinoma | Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IV Lung Non-Small Cell Cancer AJCC v7 | Stage III Lung Non-Small Cell Cancer AJCC...United States
-
Hoffmann-La RocheCompletedNon-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung CancerSpain, Italy, Poland, Brazil, Turkey, Serbia, France, Korea, Republic of, Romania, Hungary, Russian Federation, United States, United Kingdom, Germany, Greece, Japan, Thailand, Ukraine, China
-
National Cancer Institute (NCI)RecruitingStage IV Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Advanced Lung Non-Squamous Non-Small Cell Carcinoma | Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Recurrent Lung Non-Squamous Non-Small Cell CarcinomaUnited States
-
Mythic TherapeuticsRecruitingNon-Small Cell Lung Cancer | NSCLC | Advanced Non-Small Cell Lung Cancer | NSCLC Stage IV | NSCLC Stage IIIB | Advanced Non-Small Cell Squamous Lung Cancer | Advanced Non-Small Cell Non-Squamous Lung CancerUnited States, Australia, Korea, Republic of
Clinical Trials on Erlotinib
-
National Cancer Institute (NCI)University of Chicago; City of Hope Medical Center; University of Southern California and other collaboratorsCompleted
-
PfizerCompletedCarcinoma, Non-Small-Cell LungUnited States
-
Fox Chase Cancer CenterMillennium Pharmaceuticals, Inc.TerminatedNon-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer RecurrentUnited States
-
AVEO Pharmaceuticals, Inc.Biodesix, Inc.TerminatedNon-small Cell Lung CancerKorea, Republic of, United States, Australia, Taiwan, Singapore, Hong Kong, Italy
-
M.D. Anderson Cancer CenterCompletedAdvanced CancersUnited States
-
University of ChicagoNational Cancer Institute (NCI)CompletedMalignant Peritoneal MesotheliomaUnited States
-
Kyowa Kirin Co., Ltd.TerminatedNon-small-cell Lung CancerJapan
-
Merck Sharp & Dohme LLCCompleted
-
Grupo de Investigación Clínica en Oncología RadioterapiaCompletedSquamous Cell Carcinoma of the Head and NeckSpain
-
New Mexico Cancer Care AllianceCompletedAdvanced Solid Tumor MalignanciesUnited States